These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25629985)

  • 21. Treatment of adults with acute lymphoblastic leukemia: do the specifics of the regimen matter?: Results from a prospective randomized trial.
    Lamanna N; Heffner LT; Kalaycio M; Schiller G; Coutre S; Moore J; Seiter K; Maslak P; Panageas K; Golde D; Weiss MA
    Cancer; 2013 Mar; 119(6):1186-94. PubMed ID: 23280086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution.
    Seiter K; Liu D; Feldman E; Shi Q; Qureshi A; Arshad M; Walia T; Naseer N; Baskind P; Ahmed T
    Leuk Lymphoma; 2006 Mar; 47(3):425-32. PubMed ID: 16396765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
    Liedtke M; Dunn T; Dinner S; Coutré SE; Berube C; Gotlib J; Patel S; Medeiros B
    Leuk Res; 2014 Dec; 38(12):1441-5. PubMed ID: 25449689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen.
    Wiernik PH; Dutcher JP; Paietta E; Gucalp R; Markus S; Weinberg V; Azar C; Garl S; Benson L
    Leukemia; 1993 Aug; 7(8):1236-41. PubMed ID: 8350624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL.
    Giebel S; Thomas X; Hallbook H; Geissler K; Boiron JM; Huguet F; Koller E; Jaeger U; Smedmyr B; Hellmann A; Holowiecki J
    Eur J Cancer; 2012 Feb; 48(3):360-7. PubMed ID: 22196969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.
    Pangalis GA; Vassilakopoulos TP; Michalis E; Roussou P; Vrakidou E; Repousis P; Angelopoulou MK; Siakantaris MP; Korantzis J; Symeonidis A; Grigorakis V; Stefanoudakis E; Stamatellou M; Bourantas KL; Kalmantis T; Christopoulos G; Kokkinis G; Mihalakeas I; Papayiannis A;
    Leuk Lymphoma; 2003 Apr; 44(4):635-44. PubMed ID: 12769340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
    El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study.
    Liu WJ; Wang H; Wang WD; Zhu MY; Liu CC; Wang JH; Lu Y
    Sci Rep; 2016 Dec; 6():39463. PubMed ID: 28000713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Moore JO; Olsen GA
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):41-6. PubMed ID: 6385265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].
    Indrák K; Hubácek J; Mayer J; Voglová J; Jarosová M; Krahulová M; Malý J; Faber E; Penka M; Kmonícek M; Jebavý L; Szotkowski T; Knotková R; Hlusí A; Zapletalová J
    Vnitr Lek; 2001 Sep; 47 Suppl 1():48-56. PubMed ID: 11693063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
    Dekker AW; van't Veer MB; Sizoo W; Haak HL; van der Lelie J; Ossenkoppele G; Huijgens PC; Schouten HC; Sonneveld P; Willemze R; Verdonck LF; van Putten WL; Löwenberg B
    J Clin Oncol; 1997 Feb; 15(2):476-82. PubMed ID: 9053468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
    Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
    Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lim SN; Joo YD; Lee KH; Kim DY; Lee JH; Lee JH; Chi HS; Yun SC; Lee WS; Lee SM; Park S; Kim I; Sohn SK; Moon JH; Ryoo HM; Bae SH; Hyun MS; Kim MK; Kim HJ; Yang DH; Eom HS; Lee GW; Jung CW; Won JH; Kim H; Lee JH; Shin HJ; Jang DY
    Am J Hematol; 2015 Nov; 90(11):1013-20. PubMed ID: 26228525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival Rates of Adults With Acute Lymphoblastic Leukemia in a Low-Income Population: A Decade of Experience at a Single Institution in Mexico.
    Jaime-Pérez JC; Jiménez-Castillo RA; Herrera-Garza JL; Gutiérrez-Aguirre H; Marfil-Rivera LJ; Gómez-Almaguer D
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):60-68. PubMed ID: 27600987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y; Oyan B; Kars A; Tekuzman G; Canpinar H; Kansu E
    Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
    Avilés A; Neri N; Nambo JM; Huerta-Guzman J; Talavera A; Cleto S
    Leuk Lymphoma; 2005 Jul; 46(7):1023-8. PubMed ID: 16019553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.